Nautilus Biotechnology, INC Schedule 13D activist filings

Several investment funds affiliated with Andreessen Horowitz have reported a reduction in their beneficial ownership of Nautilus Biotechnology, Inc. common stock.

Andreessen Horowitz entities sold 5 million shares of Nautilus Biotechnology in a block trade, reducing their stake.

Sujal Patel, a key insider, increased his beneficial ownership in Nautilus Biotechnology, Inc. to 16.3% through recent option grants and open market purchases.

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.6% through a recent option grant.

Perceptive Advisors has filed an amended Schedule 13D, disclosing an updated beneficial ownership of 10.1% in Nautilus Biotechnology, Inc. and the departure of Michael Altman from the company's Board of Directors.

Parag Mallick, a key insider, has increased his beneficial ownership in Nautilus Biotechnology, Inc. to 17.4% of outstanding common stock, primarily through direct holdings and a recent option grant.

Sujal Patel, co-founder of Nautilus Biotechnology, Inc., has increased his beneficial ownership in the company to 15.7% through direct holdings, a family trust, and a recent option grant.

Perceptive Advisors, a significant shareholder in Nautilus Biotechnology, announced that its Managing Director, Michael Altman, will not seek re-election to the company's board of directors at the upcoming 2025 Annual Meeting.